Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae

European Respiratory Journal

Volumn 27, Issue 5, 2006, Pages 1020-1025

  Fukuda, Y ^a   Yanagihara, K ^a,b   Higashiyama, Y ^a   Miyazaki, Y ^a   Hirakata, Y ^a   Mukae, H ^a   Tomono, K ^a   Mizuta, Y ^a   Tsukamoto, K ^a,b   Kohno, S ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Azithromycin; Clarithromycin; Macrolide resistant; Pneumolysin; Streptococcus pneumoniae; Sub minimum inhibitory concentration

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; MACROLIDE; PNEUMOLYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LOBAR PNEUMONIA; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; SURVIVAL; WESTERN BLOTTING;

BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; STREPTOCOCCUS PNEUMONIAE; STREPTOLYSINS;

EID: 33845480503     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00116805     Document Type: Article

References (30)

1. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333: 1618-1624.
2. Niederman MS, Bass JB Jr, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 1993; 48:1418-1426.
3. Doern GV, Heilmann KP, Huynh K, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001; 45: 1721-1729.
4. Farrell DJ, Jenkins SG. Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002. J Antimicrob Chemother 2004; 54: Suppl. 1, i17-i22.
5. Lonks JR, Garau J, Medeiros AA. Implications of anti-microbial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides. J Antimicrob Chemother 2002; 50: Suppl. 2, 87-92.
6. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35: 556-564.
7. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-1433.
8. Nuermberger E, Bishai WR. The clinical significance of macrolide-resistant Streptococcus pneumoniae: it's all relative. Clin Infect Dis 2004; 38: 99-103.
9. Ewig S, Ruiz M, Torres A, et al. Pneumonia acquired in the community through drug-resistant Steeptococcus pneumoniae. Am J Respir Crit Care Med 1999; 159: 1835-1842.
10. Anzueto A, Niederman MS, Tillotson GS. Etiology, susceptibility, and treatment of acute tacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis Study Group. Clin Ther 1998; 20: 885-900.
11. Tateda K, Ishii Y, Matsumoto T, Kobayashi T, Miyazaki S, Yamaguchi K. Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response. J Infect Chemother 2000; 6: 1-7.
12. Mizukane R, Hirakata Y, Kaku M, et al. Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994; 38: 528-533.
13. Feldman C, Mitchell TJ, Andrew PW, et al. The effect of Streptococcus pneumoniae pneumolysin on human respiratory epithelium in vitro. Microb Pathog 1990; 9: 275-284.
14. Canvin JR, Marvin AP, Sivakumaran M, et al. The role of pneumolysin and autolysin in the pathology of pneumonia and septicemia in mice infected with a type 2 pneumococcus. J Infect Dis 1995; 172: 119-123.
15. Kadioglu. A, Gingles NA, Grattan K, Kerr A, Mitchell TJ, Andrew PW. Host cellular immune response to pneumococcal lung infection in mice. Infect Immun 2000; 68: 492-501.
16. Rubins JB, Charboneau D, Paton JC, Mitchell TJ, Andrew PW, Janoff EN. Dual function of pneumolysin in the early pathogenesis of murine pneumococcal pneumonia. J Clin Invest 1995; 95: 142-150.
17. Ubukata K, Iwata S, Sunakawa K. In vitro activities of new ketolide, telithromycin, and eight other macrolide antibiotics against Streptococcus pneumoniae having mefA and ermB genes that mediate macrolide resistance. J Infect Chemother 2003; 9: 221-226.
18. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. 5th Edn. Approved Standard M7-A5. NCCLS, Wayne, USA, 2000.
19. Lagrou K, Peetermans WE, Jorissen M, Verhaegen J, Van Damme J, Van Eldere J. Subinhibitory concentrations of erythromycin reduce pneumococcal adherence to respiratory epithelial cells in vitro. J Antimicrob Chemother 2000; 46: 717-723.
20. Alexander JE, Lock RA, Peeters CC, et al. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun 1994; 62: 5683-5688.
21. Spreer A, Kerstan H, Bottcher T, et al. Reduced release of pneumolysin by Streptococcus pneumoniae in vitro and in vivo after treatment with nonbacteriolytic antibiotics in comparison to ceftriaxone. Antimicrob Agents Chemother 2003; 47: 2649-2654.
22. Tateda K, Takashima K, Miyazaki H, Matsumoto T, Hatori T, Yamaguchi K. Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model. Antimicrob Agents Chemother 1996; 40: 1520-1525.
23. Otsu Y, Yanagihara K, Fukuda Y, et al. In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model. Antimicrob Agents Chemother 2003; 47: 3699-3703.
24. Yanagihara K, Fukuda Y, Miyazaki Y, et al. Pharmaco-dynamics and bactericidal activity of gatifloxacin in experimental pneumonia caused by penicillin-resistant Streptococcus pneumoniae. Chemotherapy 2004; 50: 107-112.
25. Hoffman HL, Klepser ME, Ernst EJ, Petzold CR, Sa'adah LM, Doern GV. Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. Antimicrob Agents Chemother 2003; 47: 739-746.
26. Shenkar R, Yum HK, Arcaroli J, Kupfner J, Abraham E. Interactions between CBP, NF-kappaB, and CREB in the lungs after hemorrhage and endotoxemia. Am J Physiol Lung Cell Mol Physiol 2001; 281: L418-L426.
27. Tsui WH, Yim, G, Wang HH, McClure JE, Surette MG, Davies J. Dual effects of MLS antibiotics: transcriptional modulation and interactions on the ribosome. Chem Biol 2004; 11: 1307-1316.
28. Berry AM, Alexander JE, Mitchell TJ, Andrew PW, Hansman D, Paton JC. Effect of defined point mutations in the pneumolysin gene on the virulence of Streptococcus pneumoniae. Infect Immun 1995; 63: 1969-1974.
29. Garcia-Suarez Mdel M, Cima-Cabal MD, Florez N, et al. Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin. Infect Immun 2004; 72:4534-4540.
30. Amsden GW. Pneumococcal macrolide resistance-myth or reality? J Antimicrob Chemother 1999; 44: 1-6.